Discontinue use if anaphylactic or other serious hypersensitivity reactions occur. Not to be initiated in patients w/ active infections; if Covid-19 patients have any other concurrent serious active infection. Not recommended in patients w/ elevated ALT or AST >5 x ULN, ANC <0.5 x 109
/L & platelet count <50 x 103
/microliter; elevated ALT or AST >10 x ULN, ANC <1 x 109
/L in Covid-19 patients. Patients w/ elevated transaminases ALT or AST >1.5 x ULN, ANC <2 x 109
/L & platelet count <100 x 103
/microliter. Monitor ALT & AST every 4-8 wk for 1st 6 mth then every 12 wk thereafter; neutrophil & platelet count 4-8 wk after start of therapy & thereafter for RA; during 2nd administration & thereafter for pJIA & sJIA. History of intestinal ulceration or diverticulitis; recurring infection or underlying condition eg, diabetes. Viral reactivation eg, HBV. Demyelinating disorders. May develop macrophage activation syndrome in sJIA patients. Screen for latent TB infection prior to starting therapy. Assess lipid parameters 4-8 wk following initiation of therapy. Not to be given concurrently w/ live attenuated vaccines. Active hepatic disease or impairment. Severe renal impairment. Not to be used during pregnancy. Lactation. Childn <2 yr.